HC Wainwright Predicts Journey Medical Q3 Earnings

Key Points

• HC Wainwright forecasts Journey Medical Corporation will report Q3 2025 earnings of ($0.08) per share, maintaining a "Buy" rating with a price target of $13.00.
• The company's latest earnings report showed a loss of ($0.16) per share for the quarter, missing consensus estimates, despite revenue exceeding expectations.
• Recent adjustments from analysts include a boost in price targets and ratings, but Zacks Research downgraded the stock from "hold" to a "strong sell" rating.

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Equities researchers at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Journey Medical in a research note issued on Monday, August 25th. HC Wainwright analyst B. Folkes forecasts that the company will post earnings of ($0.08) per share for the quarter. HC Wainwright has a "Buy" rating and a $13.00 price objective on the stock. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. HC Wainwright also issued estimates for Journey Medical's Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.45) EPS, FY2026 earnings at $0.20 EPS, FY2027 earnings at $1.31 EPS, FY2028 earnings at $1.99 EPS and FY2029 earnings at $2.15 EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.09). The business had revenue of $15.01 million for the quarter, compared to analysts' expectations of $14.93 million. Journey Medical had a negative net margin of 15.49% and a negative return on equity of 48.69%.

Several other equities research analysts have also recently commented on the company. Lake Street Capital boosted their price target on Journey Medical from $9.00 to $13.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. Alliance Global Partners reissued a "buy" rating on shares of Journey Medical in a research note on Thursday, May 15th. Zacks Research cut Journey Medical from a "hold" rating to a "strong sell" rating in a research note on Friday, August 15th. Finally, Wall Street Zen cut Journey Medical from a "buy" rating to a "hold" rating in a research note on Sunday, July 6th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $12.17.

Journey Medical Trading Up 0.3%

Shares of NASDAQ DERM opened at $7.42 on Wednesday. The stock has a market cap of $180.90 million, a price-to-earnings ratio of -19.53 and a beta of 0.80. The business has a 50 day simple moving average of $7.20 and a 200 day simple moving average of $6.63. Journey Medical has a 52 week low of $3.54 and a 52 week high of $8.90. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.95 and a current ratio of 1.27.

Institutional Investors Weigh In On Journey Medical

Hedge funds have recently modified their holdings of the business. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Journey Medical in the second quarter valued at approximately $29,000. Bank of America Corp DE boosted its position in shares of Journey Medical by 4,707.0% in the second quarter. Bank of America Corp DE now owns 4,134 shares of the company's stock valued at $30,000 after acquiring an additional 4,048 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Journey Medical in the second quarter valued at approximately $36,000. JPMorgan Chase & Co. bought a new stake in shares of Journey Medical in the second quarter valued at approximately $41,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Journey Medical in the second quarter valued at approximately $48,000. 7.25% of the stock is owned by institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.